Floatz logo

NADROPARIN

Anticoagulation

other_biologicalN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Anticoagulation cohort.

Asset / SponsorPhaseRating
Rivaroxaban
Bristol-Myers Squibb
D
WARFARIN
N/AD
Dabigatran
Bristol-Myers Squibb
D
Apixaban
Bristol-Myers Squibb
D

Same molecule, other indications

NADROPARIN is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
75 / 100
View asset →
Esophageal and Gastric VaricesDormant
BB
Indicative ·
69 / 100
View asset →
Anticoagulant-induced BleedingDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →